0001562180-20-000570.txt : 20200124 0001562180-20-000570.hdr.sgml : 20200124 20200124184342 ACCESSION NUMBER: 0001562180-20-000570 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200122 FILED AS OF DATE: 20200124 DATE AS OF CHANGE: 20200124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AGUIAR ERIC CENTRAL INDEX KEY: 0001262325 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38080 FILM NUMBER: 20546762 MAIL ADDRESS: STREET 1: 888 7TH AVENUE STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10106 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd. CENTRAL INDEX KEY: 0001689813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-01-22 false 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001262325 AGUIAR ERIC C/O AISLING CAPITAL LLC 888 SEVENTH AVENUE, 12TH FLOOR NEW YORK NY 10106 true false false false Common Shares 2020-01-22 4 M false 771.00 32.42 A 2021.00 I By Spouse Common Shares 2020-01-22 4 M false 1250.00 37.54 A 3271.00 I By Spouse Common Shares 2020-01-22 4 S false 500.00 54.9717 D 2771.00 I By Spouse Common Shares 2020-01-22 4 S false 500.00 55.991 D 2271.00 I By Spouse Common Shares 2020-01-22 4 S false 671.00 56.9943 D 1600.00 I By Spouse Common Shares 2020-01-22 4 S false 200.00 57.995 D 1400.00 I By Spouse Common Shares 2020-01-22 4 S false 150.00 58.8573 D 1250.00 I By Spouse Employee Stock Option (Right to Buy) 37.54 2020-01-22 4 M false 1250.00 0.00 D 2027-09-04 Common Shares 1250.00 2500.00 I By Spouse Employee Stock Option (Right to Buy) 32.42 2020-01-22 4 M false 771.00 0.00 D 2028-11-19 Common Shares 771.00 22500.00 I By Spouse These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.38 - $55.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.39 - $56.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.41 - $57.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.70 - $58.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.70 - $59.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The option, representing a right to purchase a total of 5,000 shares was granted on September 5, 2017, vesting in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 1,250 shares on November 22, 2019. This employee stock option is held by the Reporting Person's spouse. The option, representing a right to purchase a total of 30,000 shares was granted on November 20, 2018, vesting in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 6,729 shares on November 20, 2019. /s/ Jim Engelhart, Attorney-in-fact 2020-01-24